Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07188896 · ClinicalTrials.gov registry record · Phase 2
A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
A Phase 2 study of Clear Cell Renal Cell Carcinoma (ccRCC) and Metastatic Renal Cell Carcinoma ( mRCC), sponsored by Brian Rini.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT07188896 is a Phase 2 study of Clear Cell Renal Cell Carcinoma (ccRCC) and Metastatic Renal Cell Carcinoma ( mRCC) that is actively recruiting participants, run by Brian Rini. The registered enrollment target is 120 participants, below the 463-participant average among 5 other Clear Cell Renal Cell Carcinoma (ccRCC) trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07188896, a Phase 2 study of Clear Cell Renal Cell Carcinoma (ccRCC) and Metastatic Renal Cell Carcinoma ( mRCC), is actively recruiting participants, sponsored by Brian Rini.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
This three-arm randomized phase 2 trial will enroll advanced clear cell RCC patients (all IMDC risk groups). Patients will be randomized 2:2:1 to either Arm A (fianlimab/ cemiplimab/ ipilimumab), Arm B (fianlimab/ cemiplimab), or Arm C (standard ipilimumab/ nivolumab), respectively.
Conditions Studied
Interventions
- DRUG Cemiplimab
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG Fianlimab
Study Locations (1)
Tennessee
- Vanderbilt-Ingram Cancer Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2026-03 |
| Est. Completion | 2030-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07188896
The ClinicalTrials.gov registry entry for NCT07188896 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 463-participant average among 5 other Clear Cell Renal Cell Carcinoma (ccRCC) trials with a reported enrollment target (74% lower). The listed sponsor is Brian Rini, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Clear Cell Renal Cell Carcinoma (ccRCC) appearing as the primary indexed condition, and to 4 interventions - of which Cemiplimab is the first listed.
NCT07188896 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT07188896 about?
NCT07188896 is a clinical study titled "A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)". This three-arm randomized phase 2 trial will enroll advanced clear cell RCC patients (all IMDC risk groups). Patients will be randomized 2:2:1 to either Arm A (fianlimab/ cemiplimab/ ipilimumab), Arm B (fianlimab/ cemiplimab), or Arm C (standard ipilimumab/ nivolumab), respectively.
What is the current status of trial NCT07188896?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2026-03. Estimated completion is 2030-11.
What conditions does trial NCT07188896 study?
This clinical trial studies the following conditions: Clear Cell Renal Cell Carcinoma (ccRCC), Metastatic Renal Cell Carcinoma ( mRCC), Advanced Renal Cell Carcinoma (aRCC).
What interventions are being tested in trial NCT07188896?
The interventions under investigation include: Cemiplimab (DRUG), Nivolumab (DRUG), Ipilimumab (DRUG), Fianlimab (DRUG).
Who is sponsoring clinical trial NCT07188896?
This trial is sponsored by Brian Rini, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07188896 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clear Cell Renal Cell Carcinoma (ccRCC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
ACTIVE NOT RECRUITING · Phase 2
-
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
RECRUITING · Phase 1
-
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
RECRUITING · Phase 1
-
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
RECRUITING · Phase 1
Explore more on PlainTrial
Clear Cell Renal Cell Carcinoma (ccRCC)
All registered trials for this condition
Metastatic Renal Cell Carcinoma ( mRCC)
All registered trials for this condition
Tennessee
All trials with a study site in Tennessee
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.